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(FB). The delineation of OARs- bladder wall (BW), rectal wall (RW), 
sigmoid colon & bowel (peritoneal cavity) was done in both scans by a 
radiation oncologist. Both conventional & CT based planning were 
performed on PLATO brachytherapy planning system v14.3.7 
(Nucletron, The Netherlands). Dose volume histograms of OARs wall 
were calculated. The volume doses were defined either as minimum 
dose value in a cm3 volume receiving the highest dose (D0.1cc, D0.2cc, 
D0.5cc, D1cc, D2cc, D5cc, D10cc) or as percentage of volume of OAR 
receiving a dose (D25%, D50%, D100%). The significance of differences was 
compared using two sided paired t test. 
Results: The mean BW volume in EB & FB was 26.2cc (range 17.4-
40.4) & 44.8cc (range 38.5-49.2) respectively. When bladder was 
distended the mean difference in D0.1cc-10cc values for BW & RW 
increased marginally but were not statistically significant. However 
D0.1cc-10cc values for bowel dose (cGy) decreased significantly (0.1 cc. 
698.9 to 492.9 p=0.037, 0.2cc 666.4 to 465.7 p= 0.007, 0.5cc 617.7 to 
427.1 p=0.006, 1 cc 574.4 to 389.8 p=0.005, 2cc 521.4 to 347.9 
p=0.003, 5cc 446.4 to 286.7 p=0.002). In contrast the mean D25%, D50%, 
D100% values for both BW (411.3 vs 244.7, 254.6 vs 123.9, 78.6 vs 
26.2cGy) & bowel decreased (135.3 vs 81.2, 82.5 vs 51.6, 11.1 vs 
4.8cGy) when compared with EB &FB respectively which was 
significant at p=0.000 for all parameters for both OARs but no 
significant difference was seen for RW & sigmoid colon doses. 
Conclusions: Distension of bladder resulted in a significant reduction 
in bowel during image based ICBT without any significant increase in 
the dose to bladder wall, rectal wall and sigmoid colon and can be 
explored in clinical settings. 
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Purpose/Objective: The time course of human papillomavirus (HPV) 
DNA clearance was studied in patients with carcinoma of the cervix 
during follow-up after primary radical radiotherapy (RT). This study 
investigated the relationship between timing of HPV clearance and RT 
effectiveness. 
Materials and Methods: Seventy-two consecutive patients who were 
treated with primary radical RT for cervical cancer were enrolled in 
the study. Samples for HPV DNA examination were taken before: a) 
treatment, b) every brachytherapy, and c) and every follow-up 
examination. The times when HPV DNA was undetected were analyzed 
for association with recurrence free survival. 
Results: HPV DNA was not detected in 13 patients (18%) before RT. Of 
the 59 patients with HPV DNA detected before treatment, HPV DNA 
was not detected in 28% during treatment and in 72% after the 
treatment. Within six months after RT, HPV DNA was detected in 0% of 
all patients. Among the various time points analyzed, patients with no 
detectable HPV DNA before treatment were more accurate predictors 
of recurrence than patients with HPV DNA detected before RT. 
Conclusions: In this study we showed the time course of HPV DNA 
clearance during follow-up of patients with carcinoma of the cervix 
treated with primary radical RT. The patients in whom HPV was not 
detected had the worst prognosis. Six months after RT, HPV DNA was 
detected in 0% of the patients that had shown HPV DNA during 
treatment. In previous reports, those patients with HPV persistence 
after treatment would be considered a high risk group needing more 
effective or additional treatment. This study adds additional 
information on the relationship between detectability of HPV and RT 
effectiveness.  
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Purpose/Objective: We aim to retrospectively review the outcome of 
patients treated for EC with PORT at a single center. The secondary 
goals were identification of prognostic factors, comparison of toxicity 
profiles between vaginal cuff brachytherapy (VB) alone or combined 
with pelvic external beam radiation therapy and VB (EBRT+VB), and 
comparison of severe bladder and intestinal late toxicity (≥ G3) 
between 2D-, 3D-, and IMRT-EBRT+VB. We also investigate the 
incidence of second cancers.  
Materials and Methods: A series of 201 patients treated with PORT 
between 1999 and 2009. Patient's characteristics are summarized in 
table 1. Outcome, toxicity, and incidence of second cancers were 
confirmed by reviewing patient's charts. Overall survival (OS), 
locoregional control (LRC), disease-free survival (DFS), and cancer-
specific survival (CSS) curves were computed, and subgroups were 
compared via lograng test. Cox proportional hazards modeling was 
performed to evaluate the effect of multiple variables. 
 
Patient's characteristics Percentages (%) 
Median age 68 year-old   
Grade 1 32 
Grade 2 43.5 
Grade 3 24.5 
Lymphovascular invasion 32.5 
Stage (FIGO 1988)  
I A-B 28.85 
IC 30.85 
II 25.3 
III-IVA 15 
 
Results: At a median follow-up time of 5 years (range, 1-12), OS was 
78% (95% CI: 72-84%), DFS 72% (95% CI: 65-79%), CSS 84% (95% CI: 79-
89%), and LRC 84% (95% CI: 79-89%), In univariate analyses, significant 
prognostic factors for OS and DFS were age, grade, lymphovascular 
invasion (LVI), stage, cervical invasion, histology, and surgical 
lymphadenectomy. For CSS: histology type, cervical invasion, grade, 
stage, and presence of lymphovascular invasion. The use of 
brachytherapy was associated to better OS, DFS, and CSS in univariate 
analyses but its effect disappeared in multivariate analysis. In the 
multivariate analysis, independent factors influencing the outcome 
were age (OS, DFS), stage (OS, DFS, CSS), LVI (OS, DFS), grade (DFS, 
CSS), and lymphadenectomy (OS). By the end of follow-up, 13% of the 
patients developed severe GI or GU late toxicity, and the cumulative 
incidence of second cancers in the irradiated area was 16%. Five-year 
probability of severe (grade ≥ 3) toxicity was 0% for VB alone vs. 16% 
(95% CI: 9-23%) for EBRT+VB (p = 0.0008). By radiotherapy technique 
toxicity was: 0% for VB alone and 0% for IMRT+VB, 9% (95% CI: 1-17%) 
for 3D-EBRT+VB, and 22% (95% CI: 12-32%) for 2D-EBRT+VB, (p = 
0.0009).  
Conclusions: Local/locoregional recurrence rates remain low after 
surgery and PORT. The use of VB or EBRT+VB should be tailored to the 
surgical and pathologic features. Dependency between toxicity and 
radiotherapy technique is observed. VB alone or IMRT+VB have not 
provoked severe late toxicity. 2D-EBRT more than 3D-EBRT+VB was 
associated with increased severe toxicity. For patients with 
intermediate risk histopathologic features, VB alone seems to be 
sufficient. Comprehensive surgical staging with complete lympha-
denectomy impacts the outcome in this retrospective series. 
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Purpose/Objective: Carnitine palmitoyltransferase 1C (Cpt1c) is a 
brain-specific metabolic enzyme that is involved in energy 
homeostasis and appetite regulation (Wolfgang et al. 2006). We 
further identified Cpt1c as a gene regulated by the p53 transcription 
factor and by the AMP-dependent kinase (AMPK) (Sanchez-Macedo et 
al., accepted in CDD), which helps tumor cells to survive under 
metabolic stress, i.e. glucose deprivation and hypoxia (Zaugg et al. 
2011). To better understand the role of Cpt1c in tumorigenesis we 
need first to elucidate its physiological function, which is still unclear. 
We investigated the impact of loss of Cpt1c function in a mouse tumor 
model and analyzed the metabolic phenotype of a Cpt1c gene trap 
mouse. 
Materials and Methods: We used Nf1+/-:p53+/- mice as a tumor model. 
These Nf1;p53 heterozygous mice develop sarcomas with high 
frequency. These mice were crossbred with mice depleted of Cpt1c 
(Cpt1cgt/gt). The median survival rate of Nf1+/-:p53+/-:Cpt1cgt/gt mice 
was compared with Nf1+/-:p53+/- mice, Cpt1cgt/gt mice and a wild type 
control (C57BL/6 strain). Survival of the mice was plotted using a 
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Kaplan-Meier curve for individual genotypes against the animal age in 
months. In case of aggressive metastasis or sarcomas, the animals 
were euthanized and the tumours were isolated for analysis. Adult 
Cpt1cgt/gt and wild type mice were individually housed in calorimeter 
cages with ad libitum access to standard chow and water. During 
seven dark/light cycles we measured the respiratory exchange ratio, 
the energy expenditure rate, the food intake and the activity rate.  
Results: A higher survival rate and a lower frequency of tumors were 
observed in the Nf1+/-:p53+/-:Cpt1cgt/gt mice if compared with the 
Nf1+/-:p53+/- group. Nf1+/-:p53+/-:Cpt1cgt/gt mice were leaner than the 
Cpt1cgt/gt, the Nf1+/-:p53+/- and the WT control mice. Interestingly, 
rather than developing tumors, 28% of the Nf1+/-:p53+/-:Cpt1cgt/gt died 
due to cachexia, muscle fatigue and seizures. According to literature, 
Cpt1cgt/gt mice have a low food intake and this might be the cause of 
their lower body weight. Our group however, obtained opposite 
results: Cpt1cgt/gt mice have the same food intake and activity rate if 
compared with WT mice, but have higher energy expenditure (EE). 
This higher EE rate might be the cause of the lean phenotype. 
Conclusions: Our results indicate that Cpt1c expression in the 
Nf1+/:p53+/- mice might contribute to a more malignant phenotype of 
cancer cells. Nf1+/-:p53+/-:Cpt1cgt/gt developed tumors less frequently 
and had a higher survival rate. However, they showed a cachectic 
phenotype that still needs to be elucidated.Cpt1c-deficient mice have 
a lower body weight and higher EE rate if compared to WT mice. We 
hypothesize that tumor cells lacking Cpt1c suffer from insufficient 
nutrient supply which may cause the delay in tumor growth. 
Understanding how Cpt1c expression influences cancer cells might 
give new insights for the prediction of therapy efficiency and 
furthermore may lead to novel therapeutic approaches. Cpt1c is a 
potential target for the treatment of hypoxia- and radiation-resistant 
tumors. 
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Purpose/Objective: Medulloblastoma is one of the most common 
childhood brain malignancies. The purpose of this study is to evaluate 
the tolerability and prognostic factors for toxicity of craniospinal 
irradiation (CSI) with helical tomotherapy (HT) in the treatment of 
medulloblastoma. 
Materials and Methods: The institutional review board approved a 
retrospective chart review, which was conducted for pediatric 
patients with primary medulloblastoma treated with craniospinal HT 
from May 2007 through December 2010. Inclusion criteria were having 
a primary diagnosis of medulloblastoma, no prior history of RT, age < 
18 years old, and having a minimum follow up of 6 months for living 
patients. We found 19 patients (standard risk, N=10; high risk, N=9) 
who met such criteria. HT regimens to the neuroaxis included: 23.4 Gy 
at 1.8 Gy/fraction (N=10), 36 Gy at 1.8 Gy/fraction (N=7), and 39 Gy 
bid at 1.3 Gy/fraction (N=2). The tumor bed received 54-60 Gy at 1.5-
1.8 Gy/fraction. Toxicity was scored using the Radiation Therapy 
Oncology Group scoring system. These groups were divided according 
the toxicity location as follows: overall toxicity, cranial toxicity 
(defined as any non-hematological toxicity experienced above the 
neck), body toxicity (defined as any non-hematological toxicity 
experienced below the neck), and hematological toxicity. Spearman's 
rank correlation coefficient was used to correlate patient, tumor, and 
dosimetric factors with the grade of acute toxicity or the overall 
survival time. 
Results: The median age at diagnosis was 5 years (range, 2-14) and 
the median follow-up for living patients (N=14) was 40 months (range, 
10-62). Two and three-year overall survival was 75% and 68%, 
respectively. Only 2 patients had a local failure in the surgical bed. 
The most common acute toxicity was hematological (79%), being 
grade 2 and grade 3 in 4 (21%) and 11 (58%) cases, respectively. 
Specifically, grade 3 acute anemia, neutropenia, and thrombopenia 
was observed in 5% (N=1), 53% (N=10), and 10% (N=2), respectively. In 
addition, there were two cases of grade 2 skin toxicity, seven cases of 
grade 2 upper gastrointestinal toxicity, and one case of grade 2 
pharynx toxicity. There were no cases of grade 4 acute toxicity. No 
grade ≥2 late toxicities were observed. A longer time between 
diagnosis and radiation therapy associated with shorter overall 
survival (P =0.03). Older children were associated with higher grades 
of acute body toxicity (P =0.004), whereas longer radiation treatments 
associated with higher grades of acute hematological toxicity (P 
=0.034). 
Conclusions: Although the follow-up is relatively short, clinical 
outcomes of CSI schedule with HT are favorable, resulting in lower 
doses to the normal tissue. Acute and late toxicities are tolerable 
without severe late side effects. Further research is necessary to 
assess longer late toxicity and tumor control outcomes.  
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Purpose/Objective: To evaluate the risk of FDG-PET/CT (Positron 
Emission Tomography/Computed Tomography) scanning of paediatric 
patients in terms of radiation-induced secondary cancers. The risk of 
cancer induction was estimated and the resulting reduction of life 
expectancy was compared to the life years lost (LYL) attributable to 
the cancer therapy. 
Materials and Methods: Forty paediatric cancer patients (≤18 years 
old) with a FDG-PET/CT-scan performed between 2004 and 2012 were 
included in the study. The majority of the malignancies were 
lymphomas and sarcomas. Patient-specific information regarding the 
PET/CT scans was extracted from clinical records. For seventeen 
patients, radiotherapy plans (RTPs) were made on CT-data from a 
different scan and that additional dose was included in the risk 
estimation for the combined diagnostics.  The effective doses (EDs) 
from the FDG-PET scans were estimated using the conversion factors 
reported in ICRP 106. The EDs from the CT scans were assessed using a 
commercially available spreadsheet-based software with Monte Carlo 
simulated dose data. The risk of solid cancer induction was estimated 
according to the risk models presented in the BEIR VII report. The risk 
estimates formed the basis for estimating the lifetime attributable 
risk (LAR) of developing a solid cancer. The LAR was used with the 
cancer prognosis to estimate the LYL compared to the general 
population.  
Results: The mean estimated LAR of developing solid cancer due to 
the diagnostic scans was 0.42% (median: 0.37%, range: 0.12-1.30%) for 
the whole population. For the female and male groups, the LAR was 
0.50% (median: 0.43%, range: 0.29-1.30% and 0.34% (median: 0.33%, 
range: 0.12-0.75%), respectively. 
The effective doses are presented in table 1 and figure 1a.  
The LYL attributable to late effects from cancer therapy was 
estimated to 5.0 years and 3.7 years for females and males, 
respectively (derived from data in a report on excess mortality on 
patients in the childhood cancer survivor study). The ratios of 
attributable LYL for diagnostic scans and cancer therapy were <3%, 
see figure 1b. 
 
 Mean Median Range Total effective dose 
Diagnostic scans 
Females 
35.24 mSv 34.3 mSv 13.0-90.1 mSv 
Total effective dose 
Diagnostic scans 
Males 
42.1 mSv 39.1 mSv 12.3-78.1 mSv 
% of total effective dose 
from 18F-FDG-PET 
Females 
25.8% 21.3% 8.6-63.1% 
% of total effective dose 
from 18F-FDG-PET 
Males 
23.1% 21.2% 6.2-63.0% 
Table 1: Effective Doses. 
 
 
